TEMPLE, Texas--(BUSINESS WIRE)--Scott & White has begun recruiting patients with recurring prostate cancer to participate in a clinical trial that uses a PSA (prostate specific antigen) activated chemical injected into the prostate that attaches to prostate cancer cells and causes cell death.
